Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) shares traded down 2.6% on Monday . The stock traded as low as $18.95 and last traded at $19.37, with a volume of 239,728 shares changing hands. The stock had previously closed at $19.89.

Several research analysts have recently weighed in on the stock. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $31.00 price target (up previously from $25.00) on shares of Bellicum Pharmacueticals in a report on Tuesday, August 9th. Zacks Investment Research cut shares of Bellicum Pharmacueticals from a “hold” rating to a “sell” rating in a report on Thursday, August 11th. Jefferies Group upped their price target on shares of Bellicum Pharmacueticals from $20.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, August 9th. Citigroup Inc. upgraded shares of Bellicum Pharmacueticals from a “neutral” rating to a “buy” rating and set a $24.00 price target for the company in a report on Tuesday, August 9th. Finally, SunTrust Banks Inc. assumed coverage on shares of Bellicum Pharmacueticals in a report on Thursday, June 2nd. They issued a “buy” rating and a $20.00 price target for the company. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $27.00.

The firm’s market capitalization is $532.30 million. The company has a 50-day moving average of $15.46 and a 200 day moving average of $11.70.

Bellicum Pharmacueticals (NASDAQ:BLCM) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.04. During the same period last year, the business posted ($0.40) EPS. On average, equities analysts forecast that Bellicum Pharmacueticals Inc. will post ($2.32) EPS for the current fiscal year.

In other Bellicum Pharmacueticals news, COO Annemarie Moseley sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 2nd. The shares were sold at an average price of $13.00, for a total transaction of $325,000.00. Following the completion of the transaction, the chief operating officer now owns 18,486 shares in the company, valued at approximately $240,318. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider David M. Spencer sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $15.00, for a total transaction of $150,000.00. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Bellicum Pharmacueticals stock. Morgan Stanley boosted its stake in Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned 1.61% of Bellicum Pharmacueticals worth $8,653,000 as of its most recent filing with the SEC.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.